1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > CNS Drug News 19 JANUARY 2015

CNS Drug News 19 JANUARY 2015

  • January 2015
  • -
  • Espicom Business Intelligence
  • -
  • 24 pages

Industry Trend Analysis - Expanded Portfolio Will Help Biogen Idec Sustain Growth
Industry Brief - Neuropore/UCB Enter Worldwide Collaboration And Agreement
Industry Brief - FDA Approves AbbVie's Duopa For Motor Fluctuations In Advanced PD Patients
Industry Brief - FDA Approves Rytary For PD
Industry Brief - Phase II/III And III Trials Of Rasagiline For PD Start In Japan
Industry Trend Analysis - Genomic Data Partnerships Will Bolster Drug Development
Industry Brief - Newron Initiates Phase II Study Of sNN0031 In PD
Industry Trend Analysis - Investment In Alzheimer's R&D To Continue With Focus On Mild Disease
Industry Brief - Adamas Receives USD30mn Milestone Payment From Actavis
Industry Brief - Treeway/uniQure Collaborate To Develop Gene Therapy For ALS
Industry Brief - Isis Earns Milestone For Advancing ISIS-SMNRx In Children With SMA
Industry Brief - DSMB Recommends Continuation Of Masitinib Phase III Study In ALS
Industry Brief - Newron Initiates Phase II Study Of sNN0029 In ALS
Industry Brief - Mundipharma Receives Positive EC Decision On Targin For RLS
Industry Trend Analysis - Resubmitted Cariprazine Can Expect Slow Sales Growth
Industry Brief - Neos Submits NDA For Methylphenidate XR-ODT For ADHD
Industry Brief - New Fanapt Patent Listed In FDA's Orange Book
Industry Brief - Sunovion Files Lurasidone Patent Infringement Lawsuits
Industry Brief - Alkermes Reports Positive Results From ALKS 3831 Phase II Trial In Schizophrenia
Industry Brief - Newron Reports NW-3509 Phase I Results; Phase II Study In Schizophrenia Planned
Industry Brief - Acura Partners With Egalet To Commercialise Oxaydo
Industry Brief - Actavis Challenges US Abstral Patents
Industry Brief - FDA Accepts With Priority Review Pernix' Treximet sNDA For Use In Adolescents
Industry Brief - First Of Three Sativex Phase III Cancer Pain Trials Misses Primary Endpoint
Industry Brief - Trevena Initiates Second Phase IIb Study Of TRV130 For Acute Postoperative Pain
Industry Brief - FDA Accepts Aptiom sNDA For Review
Industry Brief - Perampanel Phase III Trial Conducted In Asia Meets Primary Endpoint
Industry Brief - Helsinn Reaches Palonosetron Settlement With Sandoz
Industry Brief - FDA Grants ODD To Auspex' SD-809 For Tourette's Syndrome In Paediatric Population
Industry Trend Analysis - Nucynta Deal Will More Than Double Depomed's Annual Net Product Sales
Industry Brief - Roche To Acquire Trophos
Industry Brief - Otsuka Completes Avanir Acquisition
Industry Brief - CoLucid Raises Funds For Oral Lasmiditan Phase III Programme In Migraine
Industry Brief - Amorfix To Centralise Operations In South San Francisco/Focus On Neurodegenerative Disease
Industry Brief - NeuroPhage Raises Funds To Advance NPT088 Into The Clinic
Industry Brief - CNS Conferences - April 2015

Table Of Contents

CNS Drug News 19 JANUARY 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized ...

Schizophrenia - US Drug Forecast and Market Analysis to 2025

Schizophrenia - US Drug Forecast and Market Analysis to 2025

  • $ 4995
  • Industry report
  • November 2016
  • by Global Data

Schizophrenia - US Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.